Prescription Drug Name:

Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution

ID:

cd62953d-3cdb-46b9-9996-6435fde9831f

Code:

34391-3

DESCRIPTION


id: 0c7efa8b-8e03-4be6-95a5-56485a2cdf23
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is a sterile antimicrobial solution for topical ophthalmic use. Trimethoprim sulfate, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine sulfate (2:1), occurs as a white, odorless, crystalline powder with a molecular weight of 678.72. The structural formula is as follows: Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formula is as follows: Each mL contains: Actives: Trimethoprim Sulfate equivalent to Trimethoprim 1 mg (0.1%) and Polymyxin B Sulfate 10,000 units. Preservative: Benzalkonium Chloride 0.04 mg (0.004%). Inactives: Sodium Chloride, Sulfuric Acid and Sodium Hydroxide may be added to adjust pH (3.0 to 5.5), and Purified Water USP.

CLINICAL PHARMACOLOGY


id: b9e71cdb-5597-49fc-bfcf-eff0cbc3bb8d
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Trimethoprim is a synthetic antibacterial drug active against a wide variety of aerobic gram-positive and gram-negative ophthalmic pathogens. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the enzyme dihydrofolate reductase. This binding is very much stronger for the bacterial enzyme than for the corresponding mammalian enzyme. For that reason, trimethoprim selectively interferes with bacterial biosynthesis of nucleic acids and proteins. Polymyxin B, a cyclic lipopeptide antibiotic, is rapidly bactericidal for a variety of gram-negative organisms, especially Pseudomonas aeruginosa. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane. When used topically, trimethoprim and polymyxin B absorption through intact skin and mucous membranes is insignificant. Blood samples were obtained from 11 human volunteers at 20 minutes, 1 hour and 3 hours following instillation in the eye of 2 drops of ophthalmic solution containing 1 mg trimethoprim and 10,000 units polymyxin B per mL. Peak serum concentrations were approximately 0.03 mcg/mL trimethoprim and 1 unit/mL polymyxin B.

INDICATIONS AND USAGE


id: fd2f4b98-7b7a-4cec-8eb0-7bd00a3d1112
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenza and Pseudomonas aeruginosa.* *Efficacy for this organism in this organ system was studied in fewer than 10 infections.

CONTRAINDICATIONS


id: 6ed6a7a2-ad5f-4692-bf87-3510e682440b
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS


id: ff03953b-dc03-415a-95b3-9d4f918c0f60
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

NOT FOR INJECTION INTO THE EYE. If a sensitivity reaction to Trimethoprim and Polymyxin B Sulfate Ophthalmic Solution occurs, discontinue use. Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is not indicated for the prophylaxis or treatment of ophthalmic neonatorum.

ADVERSE REACTIONS


id: 48f3c78e-c16c-4d51-9c48-71450149d8cc
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

The most frequent adverse reaction to Trimethoprim Sulfate and Polymxin B Sulfate Ophthalmic Solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Photosensitivity has been reported in patients taking oral trimethoprim.

HOW SUPPLIED


id: 09ef63f5-1805-4bfa-b98f-44a9191eed9e
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is supplied as a sterile solution in plastic dropper bottles in the following size: 10 mL in a 10 mL bottle NDC 68788-0536-1